We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

59 hedge funds and large institutions have $139M invested in VYNE Therapeutics in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more capital invested

Capital invested by funds: $68.4M → $139M (+$70.6M)

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

60% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 15

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

5% more funds holding

Funds holding: 56 → 59 (+3)

0.06% more ownership

Funds ownership: 0.99% → 1.06% (+0.06%)

Holders
59
Holders Change
+3
Holders Change %
+5.36%
% of All Funds
1.28%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
10
Increased
24
Reduced
15
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
+$6.21M
2
O
OrbiMed
New York
+$4.23M
3
MP
Mangrove Partners
Connecticut
+$3.74M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.52M
5
DM
Deerfield Management
New York
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$5.23M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$1.07M
3
GPP
Great Point Partners
Connecticut
-$982K
4
AIM
Alambic Investment Management
California
-$703K
5
JP Morgan Chase
JP Morgan Chase
New York
-$564K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$308K +$3.84K +8 +1%
Bank of America
27
Bank of America
North Carolina
$306K -$21.6K -45 -8%
PPA
28
Parametric Portfolio Associates
Washington
$303K +$148K +309 +137%
Goldman Sachs
29
Goldman Sachs
New York
$301K +$16.3K +34 +7%
Morgan Stanley
30
Morgan Stanley
New York
$280K -$363K -756 -60%
OAM
31
Oxford Asset Management
United Kingdom
$268K +$227K +474 New
TD Asset Management
32
TD Asset Management
Ontario, Canada
$226K +$3.84K +8 +2%
Two Sigma Advisers
33
Two Sigma Advisers
New York
$221K +$72K +150 +62%
Wells Fargo
34
Wells Fargo
California
$184K +$52.3K +109 +50%
TCIM
35
TIAA CREF Investment Management
New York
$179K +$152K +317 New
Squarepoint
36
Squarepoint
New York
$157K +$38.4K +80 +40%
EGM
37
Engineers Gate Manager
New York
$147K +$125K +260 New
Ameriprise
38
Ameriprise
Minnesota
$141K – – –
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$126K – – –
Deutsche Bank
40
Deutsche Bank
Germany
$106K -$107K -222 -54%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$100K +$85.4K +178 New
ARTA
42
A.R.T. Advisors
New York
$99K +$84K +175 New
TA
43
Teachers Advisors
New York
$97K – – –
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$96K +$4.32K +9 +6%
Ohio Public Employees Retirement System (OPERS)
45
Ohio Public Employees Retirement System (OPERS)
Ohio
$91K +$77.3K +161 New
Two Sigma Investments
46
Two Sigma Investments
New York
$85K -$206K -429 -74%
AIG
47
American International Group
New York
$49K -$960 -2 -2%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$27K – – –
Barclays
49
Barclays
United Kingdom
$27K +$20.2K +42 +1,050%
TRCT
50
Tower Research Capital (TRC)
New York
$21K -$53.8K -112 -76%
1
2
3

VYNE Hedge Fund Activity: Q1 2019 in Review

59 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2019, worth a combined $139M — up 103% from $68.4M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new VYNE positions and 7 closed out — a net gain of 3 holders — while 24 added to existing stakes and 15 trimmed.

The largest buyer was First Manhattan, adding an estimated $6.21M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $5.23M sold.

  • 59 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2019, up from 56 in Q4 2018.
  • Funds reported $139M of VYNE Therapeutics stock for Q1 2019, up 103% quarter-over-quarter.
  • 10 funds opened new VYNE Therapeutics positions in Q1 2019 and 7 closed out, a net change of +3 holders.
  • The largest VYNE Therapeutics buyer in Q1 2019 was First Manhattan, an estimated $6.21M added.
  • The largest VYNE Therapeutics seller in Q1 2019 was Novo Holdings A/S, an estimated $5.23M sold.

Based on aggregated 13F filings for Q1 2019.